- 503Pharma
- Posts
- 503Pharma Weekly Compounding Pharmacy Roundup
503Pharma Weekly Compounding Pharmacy Roundup
Your trusted source for compounding pharmacy education, news and insights.
503Pharma .
July 30, 2026
STABILITY STUDY CONSORTIUM — FOUNDING MEMBER SPOTS
The 503Pharma Group Stability Study Consortium launches with 20 founding seats at $4,000/year — three Category 3 stability studies, extended BUD data you can reference. A single solo study costs more than this entire membership.
Full details and FAQs here. Key points:
- $4,000/year for at least 3 studies
- Limited to 20 founding members
- This is the lowest price this program will ever be
If interested, reply to this email and we’ll send you the enrollment details.
Lead Story — The 8 FDA Objections in PCAC
Last week’s PCAC meeting provided a window into the FDA’s thinking on peptides. We organized their objections into eight categories — effectively a checklist of what the FDA believes a peptide needs to clear before it belongs on the 503A Bulks List.
Category | FDA Objections | What Would Fix It |
|---|---|---|
1. Identity | Many peptides have no official name. Free base and salt forms are legally different substances, but certificates (COAs) blur them and acetate ratios are often undefined. | Formal name and a certificate matching the exact form on the label. |
2. Quality | In COAs, purity may read 98%+, but no one characterized the remaining 2%: no endotoxin, no aggregates, no ICH Q3A impurity testing across all 14 ballots. | COAs scored against ICH Q3A with impurities identified, not lumped. |
3. Stability | No stability-indicating method, no formal study. Every shelf-life claim traced to a vendor product page. | Independent stability data at real-world pharmacy storage temperatures. This is one of the reasons we launched the 503Pharma Stability Consortium. |
4. Formulation feasibility | Three peptides proposed above their reported solubility. Two nasal sprays had zero container-closure data. | Solubility-verified formulations and container-closure testing. |
5. Immunogenicity | Uncontrolled impurities and aggregates can trigger anti-drug antibodies. Because these peptides mimic native molecules, those antibodies could neutralize the body's own version. | Controlled aggregate and impurity data. |
6. Clinical evidence | Abstract-only trials couldn't be assessed. Russian-language studies were excluded. 503A pharmacies don't report adverse events, so safety can't be inferred from silence. | Peer-reviewed trials by nominated route, plus adverse-event reporting. |
7. Historical use | Most are 21st-century molecules with thin U.S. compounding history. None has passed through a 503B outsourcing facility. | Time and a clean, documented compounding record. |
8. Authority gap | FDA said on the record it can't require pharmacies to register, report adverse events, or submit to surveillance inspections. | Private registries and standards that fill the gaps the agency can't. |
Categories synthesized from FDA's framing presentations (OPQ's Russell Wesdyk) and committee discussion across the July 23–24 sessions. Source: FDA briefing documents and PCAC meeting transcripts.
Most of these are paperwork and testing problems, not scientific dead ends. Several are within reach of what a pharmacy can build or demand from its suppliers. The docket (FDA-2015-N-3534) stays open, and FDA committed to another PCAC by February 2027 on five more peptides.
This Week's Updates
PCAC PEPTIDE VOTE
Advisory Committee Recommends Six of Seven Peptides for 503A Bulks List — Over FDA Staff Objections
In a historic two-day session July 23–24, the PCAC voted to recommend listing BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax on the 503A Bulks List. Only Emideltide (DSIP) was rejected (6–7–1). FDA staff had recommended against all fourteen substance/salt ballots — the first time the committee has overruled the agency toward inclusion. The votes are advisory; FDA must now conduct notice-and-comment rulemaking with no stated deadline.
RETATRUTIDE
Lilly's Retatrutide Clears Two More Phase 3 Trials — BLA Planned Q1 2027
Retatrutide (GIP/GLP-1/glucagon triple agonist) results reported July 23 — the fifth positive Phase 3 in the program. Prescriber and patient interest will build well ahead of any approval.
Trial | Population | Weight Loss | A1C Reduction |
|---|---|---|---|
TRIUMPH-3 | Severe obesity + established CV disease | 22.6% at 80 wks | — |
TRIUMPH-2 | T2D with obesity | Up to 20.8% | Up to 1.6%- |
Intel Briefs
API QUALITY GAP
Third-Party Testing Data Entered the Record — 78% of Peptide Products Missed Label Claim
Summit Works USA, a Naperville, IL API manufacturer, presented blinded testing of 46 products from 7 vendors across the research-grade peptide market. Ten of 46 met label claim. All seven KPV products were over-potent (up to +80%). Four products contained no target peptide or a different peptide entirely. Undeclared trifluoroacetate (TFA) residues reached 14 mg/g.
The Alliance for Pharmacy Compounding explained the root cause directly: "Research grade API is used in the grey market because for the peptides, research grade material is all that is available."
Legislative & Litigation Watch
Where the bills and cases stand. Updated weekly as developments occur.
Bill / Case | Status | What It Does |
|---|---|---|
SAFE Drugs Act | Advanced by Senate HELP Committee 17–5 (amended), Jul 22 | Codifies the "essentially a copy" standard and adds interstate compounding reporting requirements. Now eligible for a full Senate floor vote — the first of these compounding bills to clear committee this session. |
GLP-1 503B Exclusion | Comment period closes Jul 30 | Would permanently exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List. FDA granted a 30-day extension. This is the last week to file — no finalization timeline stated. |
Novo Nordisk v. Eli Lilly | Pending | False-advertising suit over dose-comparison claims in Zepbound/Mounjaro marketing. Watched by compounders because the dose-equivalence question also shapes how compounded GLP-1 potency is framed. |
Shortage Watch
Standing tracker from the FDA Drug Shortage Database. Compounding-relevant substances and hospital-use injectables.
The shortage story shifted this week from the long-standing local-anesthetic backorders to a cluster of hospital-use injectables reaching their FDA-posted resolution or expiration dates. Two land in the next few days; three others carry September recovery estimates that make them formulary-planning items, not purchasing ones:
Drug | Status | Recovery |
|---|---|---|
Dantrolene Sodium Injection | Shelf-life extension expiring | Jul 31, 2026 |
Atropine Sulfate Injection | Active — manufacturing delay | Sep 2026 |
Carboplatin Injection | Active — increased demand | Sep 2026 |
Lorazepam Injection | Active — manufacturing delay | Sep 2026 |
Furosemide Injection | Active — backorder | Jul 30, 2026 |
Dantrolene is the one to flag: it is the sole injectable treatment for malignant hyperthermia, and the FDA-granted shelf-life extension on existing lots lapses July 31.
Clinical Trial Watch
What researchers study today is what prescribers ask you to compound tomorrow.
Trial | Details | Why It Matters |
|---|---|---|
Injectable Testosterone for Opioid-Induced Hypogonadism | Testosterone undecanoate 250 mg/mL vs. placebo in men with chronic opioid-induced hypogonadism and pain. Record updated Jul 27. | Injectable TRT is bread-and-butter compounding, and the opioid-pain population sits squarely in many compounders' referral base. |
Low-Dose Naltrexone for Painful Diabetic Neuropathy | Placebo-controlled test of 4.5 mg LDN in painful diabetic neuropathy. No commercial equivalent exists at this dose — every capsule is compounded. | A positive neuropathic-pain signal would widen LDN's already-common prescriber base into endocrinology and pain management. |
Tesamorelin as Exercise Adjunct in HIV-Associated Frailty | Daily SC tesamorelin (GHRH analogue) paired with home exercise for physical function and body composition. | GH secretagogues (tesamorelin, sermorelin) are a core compounded-peptide category — with a cleaner regulatory footing than the seven the PCAC just reviewed. |
✉️ That’s your 503Pharma weekly digest. Our mission is to keep compounding professionals informed, prepared, and ahead of the curve.